Geographic atrophy secondary to age-related macular degeneration
Clinical trials for Geographic atrophy secondary to age-related macular degeneration explained in plain language.
Never miss a new study
Get alerted when new Geographic atrophy secondary to age-related macular degeneration trials appear
Sign up with your email to follow new studies for Geographic atrophy secondary to age-related macular degeneration, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug aims to slow vision loss in Age-Related blindness
Disease control OngoingThis study tests a drug called BI 1584862 in 150 adults aged 50+ with geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. Participants receive either the drug or a placebo for 1 year. Doctors track changes in the retina using special …
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Syfovre safety check: Real-World study tracks eye drug in 300 patients
Disease control OngoingThis study looks at how safe and tolerable the drug pegcetacoplan (Syfovre) is for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 300 patients who are already prescribed the drug by their doctor will be followed …
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC